<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6432">
  <stage>Registered</stage>
  <submitdate>12/04/2017</submitdate>
  <approvaldate>12/04/2017</approvaldate>
  <nctid>NCT03124368</nctid>
  <trial_identification>
    <studytitle>A Proof-of-Mechanism Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With C3G or IC-MPGN</studytitle>
    <scientifictitle>A Phase 2a Proof-of-Mechanism, Open-Label Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With Low C3 Levels Due to Either C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2016-003525-42</secondaryid>
    <secondaryid>ACH471-201</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>C3 Glomerulonephritis</healthcondition>
    <healthcondition>Dense Deposit Disease</healthcondition>
    <healthcondition>Membranoproliferative Glomerulonephritis, Type II</healthcondition>
    <healthcondition>C3 Glomerulopathy</healthcondition>
    <healthcondition>Immune Complex Mediated Membranoproliferative Glomerulonephritis</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Autoimmune diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ACH-0144471

Experimental: Sentinel Group 1 - All participants will receive ACH-0144471 during the treatment period.

Experimental: Group 2 - All participants will receive ACH-0144471 during the treatment period.


Treatment: drugs: ACH-0144471
Participants will receive study drug for 14 days (Treatment Period), followed by a taper over the next 7 days (Taper Period)

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change From Baseline in Blood C3 levels at Day 14</outcome>
      <timepoint>Baseline, Day 14</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Serious Adverse Events (SAEs), Grade 3 or Higher Adverse Events (AEs), and AEs Leading to Discontinuation</outcome>
      <timepoint>up to Day 49</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time (in Days) to Achieving Peak C3 Levels From the First Day of Dosing</outcome>
      <timepoint>Day 14</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics: Area Under the Curve (AUC)</outcome>
      <timepoint>Days 1 &amp; 7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics: Maximum Plasma Concentration (Cmax)</outcome>
      <timepoint>Days 1 &amp; 7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Profile of Pharmacokinetics: Time to maximum concentration (Tmax)</outcome>
      <timepoint>Days 1 &amp; 7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in Biomarkers of Alternative Pathway (AP) activity (AP Wieslab, factor D, and Bb)</outcome>
      <timepoint>Baseline, Day 14</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Relationship between ACH-0144471 exposure and changes in C3 levels and other biomarkers of alternative pathway activity (AP Wieslab, factor D, and Bb)</outcome>
      <timepoint>Day 14</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Must have a clinical diagnosis of C3G (C3 glomerulonephritis [C3GN] or dense deposit
             disease [DDD], the 2 types of C3G) or idiopathic immune-complex membranoproliferative
             glomerulonephritis (IC-MPGN) by renal biopsy for at least 3 months prior to dosing,
             with the pathologic diagnosis verified by review of the renal biopsy by the study
             central pathologist

          -  C3 must be &lt;50% of the lower limit of normal

          -  C4 must be &gt;90% of the lower limit of normal

          -  Must be willing to comply with study-specific vaccination requirements for Haemophilus
             influenzae, Streptococcus pneumoniae, and Neisseria meningitidis strains A, C, W, and
             Y

          -  Negative pregnancy test for females prior to dosing and throughout the study</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of a major organ transplant (e.g., heart, lung, kidney, liver) or
             hematopoietic stem cell/marrow transplant. Individuals receiving renal replacement
             therapy are also excluded

          -  Evidence of monoclonal gammopathy of unclear significance (MGUS), infections,
             malignancy, autoimmune diseases, or other conditions to which C3 glomerulopathy or
             IC-MPGN may be secondary

          -  Estimated glomerular filtration rate (eGFR; using MDRD equation) &lt;45 mL/min/1.73 m2 at
             the time of screening or at any time over the preceding four-weeks

          -  Receipt of eculizumab at any dose or interval within the past 75 days prior to dosing

          -  Use of tacrolimus or cyclosporine within 2 weeks of the first dose of ACH-0144471

          -  History of febrile illness, a body temperature &gt;38Â°C, or other evidence of a
             clinically significant active infection, within 14 days prior to study drug
             administration

          -  History of meningococcal infection, or a first-degree relative or household contact
             with a history of meningococcal infection

          -  Females who are pregnant, nursing, or planning to become pregnant during the study or
             within 90 days of study drug administration or patients with a female partner who is
             pregnant, nursing, or planning to become pregnant during the study or within 90 days
             of study drug administration

        NOTE: Additional inclusion/exclusion criteria may apply, per protocol.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Basic Science</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Other</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>9/08/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>The Royal Melbourne Hospital - Melbourne</hospital>
    <postcode> - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Achillion Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of this study is to determine whether ACH-0144471 can increase blood C3
      levels in participants with low C3 levels due to either C3G or IC-MPGN.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03124368</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Angela Bulawski</name>
      <address />
      <phone>203-624-7000</phone>
      <fax />
      <email>abulawski@achillion.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>